LB Pharmaceuticals Research Development Over Time
| LBRX Stock | 19.36 0.43 2.17% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out LB Pharmaceuticals Performance and LB Pharmaceuticals Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of LB Pharmaceuticals. If investors know LBRX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about LB Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of LB Pharmaceuticals Common is measured differently than its book value, which is the value of LBRX that is recorded on the company's balance sheet. Investors also form their own opinion of LB Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is LB Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because LB Pharmaceuticals' market value can be influenced by many factors that don't directly affect LB Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between LB Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if LB Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, LB Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Research Development Analysis
Compare LB Pharmaceuticals Common and related stocks such as Rocket Pharmaceuticals, Aura Biosciences, and Annexon Research Development Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RCKT | 3.5 M | 3.5 M | 3.5 M | 5.3 M | 5.6 M | 12.6 M | 32 M | 14.2 M | 53.3 M | 58.6 M | 106.4 M | 125.5 M | 165.6 M | 186.3 M | 171.2 M | 196.9 M | 206.8 M |
| AURA | 19.1 M | 19.1 M | 19.1 M | 19.1 M | 19.1 M | 19.1 M | 19.1 M | 19.1 M | 19.1 M | 19.1 M | 18 M | 25.2 M | 42.2 M | 63.9 M | 73.3 M | 84.3 M | 44.3 M |
| ANNX | 17.9 M | 17.9 M | 17.9 M | 17.9 M | 17.9 M | 17.9 M | 17.9 M | 17.9 M | 15.5 M | 24.5 M | 49.3 M | 100.1 M | 112.5 M | 113.8 M | 119.4 M | 137.4 M | 76 M |
| SLDB | 4.2 M | 4.2 M | 4.2 M | 4.2 M | 4.2 M | 4.2 M | 20.1 M | 39.9 M | 58 M | 94.7 M | 64.9 M | 58.7 M | 78.4 M | 76.6 M | 96.4 M | 110.9 M | 65.1 M |
| LRMR | 11.4 M | 11.4 M | 11.5 M | 9.6 M | 27.4 M | 54.6 M | 39.8 M | 41.7 M | 49.5 M | 20.8 M | 31.4 M | 38.4 M | 24.2 M | 27.7 M | 73.3 M | 84.3 M | 88.5 M |
| ALT | 16.6 M | 21.2 M | 19.5 M | 15.3 M | 9.3 M | 5.1 M | 4.8 M | 18.4 M | 18.5 M | 17.8 M | 49.8 M | 74.5 M | 70.5 M | 65.8 M | 82.2 M | 94.6 M | 99.3 M |
| AUTL | 24.6 M | 24.6 M | 24.6 M | 24.6 M | 24.6 M | 2.2 M | 10.4 M | 16 M | 24.6 M | 105.6 M | 135 M | 110.8 M | 117.4 M | 130.5 M | 158.1 M | 181.9 M | 190.9 M |
| DBVT | 4.5 M | 8.7 M | 15.2 M | 24 M | 27.4 M | 36.9 M | 82.9 M | 126.3 M | 123.5 M | 112.2 M | 101.6 M | 70.3 M | 75.5 M | 60.2 M | 89.9 M | 103.4 M | 62.8 M |
| DSGN | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 6.1 M | 24.8 M | 48.6 M | 57.1 M | 44.4 M | 51 M | 33.5 M |
| KRRO | 11.8 M | 11.8 M | 11.8 M | 11.8 M | 11.8 M | 11.8 M | 11.8 M | 11.8 M | 11.6 M | 18.3 M | 36.7 M | 59.3 M | 42.2 M | 57.2 M | 63.6 M | 73.2 M | 41.4 M |
LB Pharmaceuticals Common and related stocks such as Rocket Pharmaceuticals, Aura Biosciences, and Annexon Research Development description
My Equities
My Current Equities and Potential Positions
| LB Pharmaceuticals Common | LBRX |
Specialization | Healthcare, Biotechnology |
| Business Address | One Pennsylvania Plaza, |
| Exchange | NASDAQ Exchange |
null 19.36
Additional Tools for LBRX Stock Analysis
When running LB Pharmaceuticals' price analysis, check to measure LB Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LB Pharmaceuticals is operating at the current time. Most of LB Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of LB Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LB Pharmaceuticals' price. Additionally, you may evaluate how the addition of LB Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.